Posted on 26/07/2010 in Animal Health Supplier News Idexx Laboratories has published its financial report for the second quarter of 2010, during which the firm experienced a better-than-expected fiscal performance.
The animal health company's revenues rose by six per cent year-on-year to $281.5 million (181.7 million pounds), while earnings per diluted share increased by 13 per cent in the same time frame.
Among the business units to see growth were its companion animal and water divisions, while products such as the Catalyst Dx chemistry analyser saw an improved market performance.
According to Jonathan Ayers, chairman and chief executive officer of Idexx, the company is now on target to meet its full year earnings per share guidance.
He added: "Our achievement of five per cent organic revenue growth in an economic environment that remains challenging is a testament to our continued success in bringing innovative products and services to our veterinary and other customers."
Last month, the company announced the launch of a new large-scale study of feline cardiac health, an initiative designed to improve understanding of treatment issues. Other news stories from 26/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
